Eversept Partners’s AnaptysBio ANAB Stock Holding History

Eversept Partners’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.5M	Sell	27,089 -93,838	-78%	-$5.05M	0.08%	96
2025 Q4	$5.86M	Buy	+120,927	New	+$4.71M	0.3%	66
2022 Q3	–	Sell	-182,717	Closed	-$3.71M	–	72
2022 Q2	$3.71M	Buy	182,717 +68,552	+60%	+$1.52M	0.26%	52
2022 Q1	$2.82M	Sell	114,165 -68,447	-37%	-$2.07M	0.22%	55
2021 Q4	$6.35M	Buy	182,612 +104,558	+134%	+$3.32M	0.41%	59
2021 Q3	$2.12M	Buy	+78,054	New	+$1.98M	0.15%	75
2021 Q1	–	Sell	-88,334	Closed	-$1.9M	–	87
2020 Q4	$1.9M	Buy	+88,334	New	+$2.15M	0.22%	43
2018 Q4	–	Sell	-22,524	Closed	-$2.25M	–	55
2018 Q3	$2.25M	Sell	22,524 -10,110	-31%	-$839K	0.99%	20
2018 Q2	$2.32M	Buy	+32,634	New	+$2.74M	1.06%	22

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Eversept Partners's ANAB Position: Q1 2026 in Review

Eversept Partners reduced its AnaptysBio (ANAB) stake by 78% in Q1 2026, selling an estimated $5.05M and leaving 27,089 shares worth $1.5M. The position accounts for 0.08% of the portfolio, ranked #96.

Eversept Partners first reported a position in ANAB in Q2 2018 and has held it in 9 quarters since. The position peaked at $6.35M in Q4 2021. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

Eversept Partners held 27,089 shares of AnaptysBio worth $1.5M as of Q1 2026.
Eversept Partners sold 93,838 AnaptysBio shares in Q1 2026, an estimated $5.05M.
AnaptysBio made up 0.08% of Eversept Partners's portfolio in Q1 2026, its #96 holding.
Eversept Partners first reported a position in AnaptysBio in Q2 2018 and has held it in 9 quarters since.
Eversept Partners's AnaptysBio position peaked at $6.35M in Q4 2021.
207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.